Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

NCT05668403 is registered in ClinicalTrials.gov with Shanghai Jiaolian Drug Research and Development Co., Ltd as lead sponsor.

NCT NCT05668403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
March 2, 2023
Completion date
December 30, 2027
Enrollment
52 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy